α1-antitrypsin inhibits the activity of the matriptase catalytic domain in vitro

American Journal of Respiratory Cell and Molecular Biology

Volumn 39, Issue 6, 2008, Pages 631-637

  Janciauskiene, Sabina ^a,d   Nita, Izabela ^a   Subramaniyam, Devipriya ^a   Li, Qian ^b   Lancaster Jr , Jack R ^b,c   Matalon, Sadis ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Malmö University Hospital   (Sweden)

Author keywords

1 antitrypsin; Complex formation; Kinetics; Matriptase; Serine proteases

Indexed keywords

ALPHA 1 ANTITRYPSIN; DODECYL SULFATE SODIUM; EPITHELIAL SODIUM CHANNEL; MATRIPTASE; LEUKOCYTE ELASTASE; SERINE PROTEINASE;

ARTICLE; DRUG INHIBITION; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME MECHANISM; IN VITRO STUDY; IN VIVO STUDY; INTROSPECTION; PHYSIOLOGY; PROTEIN DOMAIN; REGULATORY MECHANISM; WESTERN BLOTTING; AMINO ACID SEQUENCE; CHEMISTRY; ENZYME ACTIVE SITE; HUMAN; KINETICS; METABOLISM; MOLECULAR GENETICS; OXIDATION REDUCTION REACTION; POLYACRYLAMIDE GEL ELECTROPHORESIS; SEQUENCE ALIGNMENT; X RAY CRYSTALLOGRAPHY;

ALPHA 1-ANTITRYPSIN; AMINO ACID SEQUENCE; BLOTTING, WESTERN; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; KINETICS; LEUKOCYTE ELASTASE; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; SEQUENCE ALIGNMENT; SERINE ENDOPEPTIDASES;

EID: 57349149443     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2008-0015RC     Document Type: Article

References (39)

1. Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 1993;53:1409-1415.
2. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999;274:18231-18236.
3. Kim MG, Chen C, Lyu MS, Cho EG, Park D, Kozak C, Schwartz RH. Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 1999;49:420-428.
4. Satomi S, Yamasaki Y, Tsuzuki S, Hitomi Y, Iwanaga T, Fushiki T. A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem Biophys Res Commun 2001;287:995-1002.
5. Yamada K, Takabatake T, Takeshima K. Isolation and characterization of three novel serine protease genes from Xenopus laevis. Gene 2000;252:209-216.
6. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify amembrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999;96:11054-11061.
7. Hung RJ, Hsu Ia W, Dreiling JL, Lee MJ, Williams CA, Oberst MD, Dickson RB, Lin CY. Assembly of adherens junctions is required for sphingosine 1-phosphate-induced matriptase accumulation and activation at mammary epithelial cell-cell contacts. Am J Physiol Cell Physiol 2004;286:C1159-C1169.
8. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W, Engelholm LH, Behrendt N, Bugge TH. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002;21:3765-3779.
9. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000;275:26333-26342.
10. List K, Hobson JP, Molinolo A, Bugge TH. Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase. J Cell Physiol 2007;213:237-245.
11. Netzel-Arnett S, Currie BM, Szabo R, Lin CY, Chen LM, Chai KX, Antalis TM, Bugge TH, List K. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem 2006;281:32941-32945.
12. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, Dickson RB, Lin CY. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001;158:1301-1311.
13. Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, Madison EL, Agus DB. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 2004;61:228-235.
14. Enyedy IJ, Lee SL, Kuo AH, Dickson RB, Lin CY, Wang S. Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. J Med Chem 2001;44:1349-1355.
15. Stoop AA, Craik CS. Engineering of a macromolecular scaffold to develop specific protease inhibitors. Nat Biotechnol 2003;21:1063-1068.
16. Sun J, Pons J, Craik CS. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry 2003;42:892-900.
17. Desilets A, Longpre JM, Beaulieu ME, Leduc R. Inhibition of human matriptase by eglin c variants. FEBS Lett 2006;580:2227-2232.
18. Jiang S, Li P, Lee SL, Lin CY, Long YQ, Johnson MD,Dickson RB, Roller PP. Design and synthesis of redox stable analogues of sunflower trypsin inhibitors (SFTI-1) on solid support, potent inhibitors of matriptase. Org Lett 2007;9:9-12.
19. Szabo R, Molinolo A, List K, Bugge TH. Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene 2007;26:1546-1556.
20. Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, Hartl D. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007;29:240-250.
21. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
22. Moraga F, Janciauskiene S. Activation of primary human monocytes by the oxidized form of alpha1-antitrypsin. J Biol Chem 2000;275:7693-7700.
23. Gettins PG. Serpin structure, mechanism, and function. Chem Rev 2002;102:4751-4804.
24. Ogushi F, Hubbard RC, Fells GA, Casolaro MA, Curiel DT, Brantly ML, Crystal RG. Evaluation of the S-type of alpha-1-antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastase. Am Rev Respir Dis 1988;137:364-370.
25. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency-a model for conformational diseases. N Engl J Med 2002;346:45-53.
26. Swystun V, Chen L, Factor P, Siroky B, Bell PD, Matalon S. Apical trypsin increases ion transport and resistance by a phospholipase C-dependent rise of Ca21. Am J Physiol Lung Cell Mol Physiol 2005;288:L820-L830.
27. Petrache I, Fijalkowska I, Medler TR, Skirball J, Cruz P, Zhen L, Petrache HI, Flotte TR, Tuder RM. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol 2006;169:1155-1166.
28. Rawlings ND, Barrett AJ. Evolutionary families of peptidases. Biochem J 1993;290:205-218.
29. Janciauskiene S. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta 2001;1535:221-235.
30. Matheson NR, Wong PS, Travis J. Enzymatic inactivation of human alpha-1-proteinase inhibitor by neutrophil myeloperoxidase. Biochem Biophys Res Commun 1979;88:402-409.
31. Padrines M, Schneider-Pozzer M, Bieth JG. Inhibition of neutrophil elastase by alpha-1-proteinase inhibitor oxidized by activated neutrophils. Am Rev Respir Dis 1989;139:783-790.
32. Carp H, Miller F, Hoidal JR, Janoff A. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci USA 1982;79:2041-2045.
33. Taggart C, Cervantes-Laurean D, Kim G, McElvaney NG, Wehr N, Moss J, Levine RL. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem 2000;275:27258-27265.
34. Congote LF. The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochem Biophys Res Commun 2006;343:617-622.
35. Janciauskiene S, Nita I, Lazrak A, Ji H-L, Matalon S. Antitrypsin decreases amiloride-sensitive currents across Xenopus oocytes injected with alpha beta gamma ENaC cRNAs. American Thoracic Society International Conference, Toronto, Canada, May 16-18, 2008. Am J Respir Crit Care Med 2008;177:A329. (Abstract).
36. Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem 1980;255:3931-3934.
37. Tseng IC, Chou FP, Su SF, Oberst MD, Madayiputhiya N, Lee MS, Wang JK, Sloane DE, Johnson MD, Lin CY. Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase in the absence of HAI-1. Am J Physiol Cell Physiol 2008;295:C423-C431.
38. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, Burke B, Nielsen BS, Gutkind JS, Bugge TH. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 2005;19:1934-1950.
39. Kataoka H, Itoh H, Koono M. Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration. Pathol Int 2002;52:89-102.